SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 88898.
  • 2
    Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485517.
  • 3
    Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29: 4456.
  • 4
    Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 2358.
  • 5
    Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 58092.
  • 6
    Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin-17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000; 12: 10929.
  • 7
    Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE Study cohort). Arthritis Rheum 2006; 54: 112231.
  • 8
    Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 1014.
  • 9
    Graber JJ, Allie SR, Mullen KM, Jones MV, Wang T, Krishnan C, et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol 2008; 196: 12432.
  • 10
    Suzuki Y, Kuroda Y, Morita A, Fujino Y, Tanioka Y, Kawamura T, et al. Fibrin glue sealing for the prevention of pancreatic fistulas following distal pancreatectomy. Arch Surg 1995; 130: 9525.
  • 11
    Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 14613.
  • 12
    Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009; 58: 130211.
  • 13
    Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108: 4308.
  • 14
    Dong C. Differentiation and function of pro-inflammatory Th17 cells. Microbes Infect 2009; 11: 5848.
  • 15
    Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001; 167: 100413.
  • 16
    Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005; 167: 1419.
  • 17
    Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005; 237: 12330.
  • 18
    Cooreman M, Di Padova FE, inventors; Novartis AG, Novartis Pharma GmbH, Cooreman M, Di Padova FE, applicants. IL-17 antagonistic antibodies [for] treating cancer. International application PCT/US2007/061276. 2007 Jan 30.
  • 19
    National Library of Medicine. National Institutes of Health clinical trials database. URL: www.clinicaltrials.gov.
  • 20
    Tak PP, Durez P, Gomez-Reino JJ, Wittmer B, Chindalore V, Di Padova F, et al. AIN457 shows a good safety profile and clinical benefit in patients with active rheumatoid arthritis (RA) despite methotrexate therapy: 16-weeks results from a randomized proof-of-concept trial [abstract]. Arthritis Rheum 2009; 60 Suppl: 1922.
  • 21
    Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 50510.
  • 22
    Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 81822.
  • 23
    Oguro A, Ohtsu T, Svitkin YV, Sonenberg N, Nakamura Y. RNA aptamers to initiation factor 4A helicase hinder cap-dependent translation by blocking ATP hydrolysis. RNA 2003; 9: 394407.
  • 24
    Miyakawa S, Oguro A, Ohtsu T, Imataka H, Sonenberg N, Nakamura Y. RNA aptamers to mammalian initiation factor 4G inhibit cap-dependent translation by blocking the formation of initiation factor complexes. RNA 2006; 12: 182534.
  • 25
    Keefe AD, Schaub RG. Aptamers as candidate therapeutics for cardiovascular indications. Curr Opin Pharmacol 2008; 8: 14752.
  • 26
    Miyakawa S, Nomura Y, Sakamoto T, Yamaguchi Y, Kato K, Yamazaki S, et al. Structural and molecular basis for hyperspecificity of RNA aptamer to human immunoglobulin G. RNA 2008; 14: 115463.
  • 27
    Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 12332.
  • 28
    Wang J, Takeuchi H, Sonobe Y, Jin S, Shijie J, Mizuno T, et al. Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A 2008; 105: 391520.
  • 29
    Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Hitchon CA, Schur PH, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum 2003; 48: 94454.
  • 30
    Kurahashi H, Nakamura Y. Channel mutations in Hsp104 hexamer distinctively affect thermotolerance and prion-specific propagation. Mol Microbiol 2007; 63: 166983.
  • 31
    Sano T, Ishiguro A. A simple and sensitive non radioactive microplate hybridization for the detection and quantification of viroid and viral RNA. Arch Phytopath Pflanz 1998; 30: 30312.
  • 32
    Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995; 155: 54836.
  • 33
    Linden A, Adachi M. Neutrophilic airway inflammation and IL-17. Allergy 2002; 57: 76975.
  • 34
    Jeffery JY, Gaffen SL. Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity. Front Biosci 2008; 13: 1707.
  • 35
    Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem 1998; 273: 2746773.
  • 36
    Westwick JK, Weitzel C, Minden A, Karin M, Brenner DA. Tumor necrosis factor α stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J Biol Chem 1994; 269: 26396401.
  • 37
    Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3: 81121.
  • 38
    Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor–associated factor (TRAF)6 in interleukin-17 signal transduction. J Exp Med 2000; 191: 12339.
  • 39
    Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y, et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 2008; 58: 75463.
  • 40
    Wright JF, Gu Y, Quazi A, Luxenberg DP, Bennett F, Ross JF, et al. Identification of an interleukin-17F/17A heterodimer in activated human CD4 T cells. J Biol Chem 2007; 282: 1344755.
  • 41
    Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M, et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 2007; 179: 77919.
  • 42
    Zhang GX, Gran B, Yu S, Li J, Siglienti I, Chen X, et al. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-β2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol 2003; 170: 215360.
  • 43
    Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008; 181: 74808.
  • 44
    Schubert D, Maier B, Morawietz L, Krenn V, Kamradt T. Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice. J Immunol 2004; 172: 45039.
  • 45
    Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 1999; 35: 53342.
  • 46
    Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008; 205: 106375.
  • 47
    Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, et al. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006; 203: 271525.
  • 48
    Moreland L. Unmet needs in rheumatoid arthritis. Arthritis Res Ther 2005; 7: 28.
  • 49
    Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al. LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62: 92939.